These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 25587045

  • 1. Syndecan-4 is a key determinant of collagen cross-linking and passive myocardial stiffness in the pressure-overloaded heart.
    Herum KM, Lunde IG, Skrbic B, Louch WE, Hasic A, Boye S, Unger A, Brorson SH, Sjaastad I, Tønnessen T, Linke WA, Gomez MF, Christensen G.
    Cardiovasc Res; 2015 May 01; 106(2):217-26. PubMed ID: 25587045
    [Abstract] [Full Text] [Related]

  • 2. Syndecan-4 signaling via NFAT regulates extracellular matrix production and cardiac myofibroblast differentiation in response to mechanical stress.
    Herum KM, Lunde IG, Skrbic B, Florholmen G, Behmen D, Sjaastad I, Carlson CR, Gomez MF, Christensen G.
    J Mol Cell Cardiol; 2013 Jan 01; 54():73-81. PubMed ID: 23178899
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase?
    López B, González A, Lindner D, Westermann D, Ravassa S, Beaumont J, Gallego I, Zudaire A, Brugnolaro C, Querejeta R, Larman M, Tschöpe C, Díez J.
    Cardiovasc Res; 2013 Jul 01; 99(1):111-20. PubMed ID: 23619422
    [Abstract] [Full Text] [Related]

  • 5. Syndecan-4 Protects the Heart From the Profibrotic Effects of Thrombin-Cleaved Osteopontin.
    Herum KM, Romaine A, Wang A, Melleby AO, Strand ME, Pacheco J, Braathen B, Dunér P, Tønnessen T, Lunde IG, Sjaastad I, Brakebusch C, McCulloch AD, Gomez MF, Carlson CR, Christensen G.
    J Am Heart Assoc; 2020 Feb 04; 9(3):e013518. PubMed ID: 32000579
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Inhibitor of lysyl oxidase improves cardiac function and the collagen/MMP profile in response to volume overload.
    El Hajj EC, El Hajj MC, Ninh VK, Gardner JD.
    Am J Physiol Heart Circ Physiol; 2018 Sep 01; 315(3):H463-H473. PubMed ID: 29775412
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. T lymphocyte regulation of lysyl oxidase in diet-induced cardiac fibrosis.
    Zibadi S, Vazquez R, Larson DF, Watson RR.
    Cardiovasc Toxicol; 2010 Sep 01; 10(3):190-8. PubMed ID: 20556665
    [Abstract] [Full Text] [Related]

  • 15. The extracellular matrix proteoglycan lumican improves survival and counteracts cardiac dilatation and failure in mice subjected to pressure overload.
    Mohammadzadeh N, Lunde IG, Andenæs K, Strand ME, Aronsen JM, Skrbic B, Marstein HS, Bandlien C, Nygård S, Gorham J, Sjaastad I, Chakravarti S, Christensen G, Engebretsen KVT, Tønnessen T.
    Sci Rep; 2019 Jun 24; 9(1):9206. PubMed ID: 31235849
    [Abstract] [Full Text] [Related]

  • 16. The extracellular matrix proteoglycan fibromodulin is upregulated in clinical and experimental heart failure and affects cardiac remodeling.
    Andenæs K, Lunde IG, Mohammadzadeh N, Dahl CP, Aronsen JM, Strand ME, Palmero S, Sjaastad I, Christensen G, Engebretsen KVT, Tønnessen T.
    PLoS One; 2018 Jun 24; 13(7):e0201422. PubMed ID: 30052659
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Syndecan-4: a novel regulator of collagen synthesis and deposition in the pressure-overloaded myocardium.
    Yabluchanskiy A, Ma Y, Lindsey ML.
    Cardiovasc Res; 2015 May 01; 106(2):178-9. PubMed ID: 25808974
    [No Abstract] [Full Text] [Related]

  • 19. Lysyl oxidase overexpression accelerates cardiac remodeling and aggravates angiotensin II-induced hypertrophy.
    Galán M, Varona S, Guadall A, Orriols M, Navas M, Aguiló S, de Diego A, Navarro MA, García-Dorado D, Rodríguez-Sinovas A, Martínez-González J, Rodriguez C.
    FASEB J; 2017 Sep 01; 31(9):3787-3799. PubMed ID: 28522596
    [Abstract] [Full Text] [Related]

  • 20. Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5.
    Engebretsen KV, Skårdal K, Bjørnstad S, Marstein HS, Skrbic B, Sjaastad I, Christensen G, Bjørnstad JL, Tønnessen T.
    J Mol Cell Cardiol; 2014 Nov 01; 76():148-57. PubMed ID: 25169971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.